Registration studies — when should patients be deemed ineligible for aggressive therapy?

Rachel J. Cook, Jennifer Gill, Vinay Prasad

Research output: Contribution to journal › Comment/debate

Abstract

The approval of therapeutic agents that are tested in patients deemed ineligible for intensive or aggressive therapy is increasingly popular. This approach enables comparisons of novel therapies with less-aggressive agents, as well as data from nonrandomized studies to be used for market authorization. Herein, we discuss three mechanisms that could be adopted to avoid the temptation of applying this strategy excessively.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Registration studies — when should patients be deemed ineligible for aggressive therapy? / Cook, Rachel J.; Gill, Jennifer; Prasad, Vinay.

In: Nature Reviews Clinical Oncology, 01.01.2019.

Research output: Contribution to journal › Comment/debate

Cook, RJ, Gill, J & Prasad, V 2019, 'Registration studies — when should patients be deemed ineligible for aggressive therapy?', Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-019-0180-x
Cook RJ, Gill J, Prasad V. Registration studies — when should patients be deemed ineligible for aggressive therapy? Nature Reviews Clinical Oncology. 2019 Jan 1. https://doi.org/10.1038/s41571-019-0180-x
Cook, Rachel J. ; Gill, Jennifer ; Prasad, Vinay. / Registration studies — when should patients be deemed ineligible for aggressive therapy?. In: Nature Reviews Clinical Oncology. 2019.
@article{ac264badb9db4a348b2a7e6449c143e5,
title = "Registration studies — when should patients be deemed ineligible for aggressive therapy?",
abstract = "The approval of therapeutic agents that are tested in patients deemed ineligible for intensive or aggressive therapy is increasingly popular. This approach enables comparisons of novel therapies with less-aggressive agents, as well as data from nonrandomized studies to be used for market authorization. Herein, we discuss three mechanisms that could be adopted to avoid the temptation of applying this strategy excessively.",
author = "Cook, {Rachel J.} and Jennifer Gill and Vinay Prasad",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41571-019-0180-x",
language = "English (US)",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Registration studies — when should patients be deemed ineligible for aggressive therapy?

AU - Cook, Rachel J.

AU - Gill, Jennifer

AU - Prasad, Vinay

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The approval of therapeutic agents that are tested in patients deemed ineligible for intensive or aggressive therapy is increasingly popular. This approach enables comparisons of novel therapies with less-aggressive agents, as well as data from nonrandomized studies to be used for market authorization. Herein, we discuss three mechanisms that could be adopted to avoid the temptation of applying this strategy excessively.

AB - The approval of therapeutic agents that are tested in patients deemed ineligible for intensive or aggressive therapy is increasingly popular. This approach enables comparisons of novel therapies with less-aggressive agents, as well as data from nonrandomized studies to be used for market authorization. Herein, we discuss three mechanisms that could be adopted to avoid the temptation of applying this strategy excessively.

UR - http://www.scopus.com/inward/record.url?scp=85061751527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061751527&partnerID=8YFLogxK

U2 - 10.1038/s41571-019-0180-x

DO - 10.1038/s41571-019-0180-x

M3 - Comment/debate

C2 - 30778146

AN - SCOPUS:85061751527

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

ER -

Access to Document